Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 6/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | DDX3X | O00571 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316815 | 0.81 | IMPDH2 (0.42) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3313045 | 0.76 | PRMT3 (0.41) | IMPDH2ROCK2PRMT3DDX3X | |
| SCHEMBL3313256 | 0.75 | PRMT3 (0.40) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3313248 | 0.75 | PRMT3 (0.40) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3315470 | 0.75 | ROCK2 (0.46) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3319897 | 0.73 | ROCK2 (0.51) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3315427 | 0.72 | HRH3 (0.45) | IMPDH2ROCK2PRMT3ROCK1 | |
| SCHEMBL3314413 | 0.72 | HTR2A (0.40) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3314417 | 0.72 | HTR2A (0.40) | IMPDH2ROCK2PRMT3ROCK1DDX3X | |
| SCHEMBL3311391 | 0.72 | PRMT3 (0.43) | IMPDH2ROCK2PRMT3ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | IMPDH2 384/4885ROCK2 6/4885PRMT3 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.